Key result
Multidisciplinary approach to anthracycline retreatment highlights strategies to monitor and prevent cardiotoxicity in relapsed AML.
Why the study?
Cardiotoxic dose equivalency for nondoxorubicin anthracyclines and incorporation of prior dexrazoxane into risk stratification remain unclear when deciding on safety of additional anthracycline treatment.
Case Report (n=1)
Highlights the complexities of calculating lifetime anthracycline dose equivalency and the role of multidisciplinary discussion in managing retreatment in patients with prior exposure and cardiotoxicity concerns.
Answers are grounded in this paper and cite their sources.
May guide multidisciplinary anthracycline retreatment decisions; hypothesis-generating and leaves open need for prospective validation.
Anthracyclines are an effective treatment for hematologic malignancies but have significant risk of cardiotoxicity that increases with lifetime dose, best characterized for doxorubicin. However, patients may receive different anthracycline formulations, and cardiotoxic dose equivalency for nondoxorubicin anthracyclines is uncertain, making it challenging to calculate a patient's lifetime dose to make decisions about safety of additional anthracycline treatment and risk stratification for monitoring and cardioprotective strategies. In addition, dexrazoxane reduces the risk of cardiovascular toxicity with anthracyclines but how to incorporate previous dexrazoxane treatment into risk stratification is unclear. Here, a young woman previously treated with anthracyclines as induction therapy for acute myeloid leukemia and concern for previous anthracycline cardiotoxicity presented with disease relapse. Because optimal therapy included retreatment with anthracyclines, this case demonstrates the multidisciplinary discussion for her case, reviewing the risks and benefits of repeat anthracycline exposure and detailing the evidence for strategies to monitor and prevent worsening cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Travers et al. (2025) conducted a case report in Acute myeloid leukemia (n=1). Anthracycline retreatment was evaluated. A multidisciplinary approach to anthracycline retreatment in a young woman with acute myeloid leukemia relapse highlights strategies to monitor and prevent worsening cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: